Head-to-head evidence
REGN5093 vs Savolitinib
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: MET · full Non-Small Cell Lung Cancer pipeline
REGN5093
Developed by Regeneron Pharmaceuticals
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: July 2027 · NCT04077099 (registry estimate)
Savolitinib · Orpathys
Marketed by AstraZeneca and partners
NCT05015608 · Phase 3 · completed
The trial randomized 216 participants to savolitinib plus osimertinib or active chemotherapy, but treatment was not blinded. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Next expected readout: December 2026 · NCT04322890 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: REGN5093's landscape · Savolitinib's landscape